Exact Sciences
EXAS
$0.63 (-1.17%)
1D
1W
3M
1Y
5Y
ALL
Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. It is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 2 days ago • EXAS
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin DownZacks Investment Research • 3 days ago • EXAS
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue EstimatesInvestors Business Daily • 3 days ago • EXAS
Exact Sciences Stock, A Cathie Wood Darling, Tumbles On Wide Quarterly LossesCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.